Research ArticleBrief Communications
Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
Paola A. Erba, Martina Sollini, Enrico Orciuolo, Claudio Traino, Mario Petrini, Giovanni Paganelli, Emilio Bombardieri, Chiara Grana, Leonardo Giovannoni, Dario Neri, Hans D. Menssen and Giuliano Mariani
Journal of Nuclear Medicine June 2012, 53 (6) 922-927; DOI: https://doi.org/10.2967/jnumed.111.101006
Paola A. Erba
Martina Sollini
Enrico Orciuolo
Claudio Traino
Mario Petrini
Giovanni Paganelli
Emilio Bombardieri
Chiara Grana
Leonardo Giovannoni
Dario Neri
Hans D. Menssen

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 6
June 1, 2012
Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
Paola A. Erba, Martina Sollini, Enrico Orciuolo, Claudio Traino, Mario Petrini, Giovanni Paganelli, Emilio Bombardieri, Chiara Grana, Leonardo Giovannoni, Dario Neri, Hans D. Menssen, Giuliano Mariani
Journal of Nuclear Medicine Jun 2012, 53 (6) 922-927; DOI: 10.2967/jnumed.111.101006
Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
Paola A. Erba, Martina Sollini, Enrico Orciuolo, Claudio Traino, Mario Petrini, Giovanni Paganelli, Emilio Bombardieri, Chiara Grana, Leonardo Giovannoni, Dario Neri, Hans D. Menssen, Giuliano Mariani
Journal of Nuclear Medicine Jun 2012, 53 (6) 922-927; DOI: 10.2967/jnumed.111.101006
Jump to section
Related Articles
Cited By...
- An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
- Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
- Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
- TGF-{beta} induces oncofetal fibronectin that, in turn, modulates TGF-{beta} superfamily signaling in endothelial cells
- Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- Therapeutic vaccination targeting the tumour vasculature
- Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
- Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study